Nateglinide, a New Mealtime Glucose Regulator: Lack of Pharmacokinetic Interaction with Digoxin in Healthy Volunteers

By Zhou H.  

Clinical Drug Investigation, Vol. 19, Iss. 6, 2000-06 ,pp. : 465-471

Adis International

Access to resources Recommend Favorite

Selectivity of prandial glucose regulators: nateglinide, but not repaglinide, accelerates exocytosis in rat pancreatic A-cells

By Bokvist K.   Hoy M.   Buschard K.   Holst J.J.   Thomsen M.K.   Gromada J.  

European Journal of Pharmacology, Vol. 386, Iss. 1, 1999-12 ,pp. : 105-111

Elsevier

Access to resources Recommend Favorite

Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects

By Sabia Helene   Sunkara Gangadhar   Ligueros-Saylan Monica   Wang Yibin   Smith Harold   McLeod James   Prasad Pratapa  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 6, 2004-09 ,pp. : 407-412

Springer Publishing Company

Access to resources Recommend Favorite

Postprandial glucose control - the promise of nateglinide

By  

Inpharma, Vol. 1, Iss. 1309, 2001-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Fixed-Dose Combination Tablet of Repaglinide and Metformin is Bioequivalent to Concomitantly Administered Individual Tablets of Repaglinide and Metformin: Randomized, Single-Blind, Three-Period Crossover Study in Healthy Subjects

By Hoelscher David  

Clinical Drug Investigation, Vol. 28, Iss. 9, 2008-01 ,pp. : 573-582

Adis International

Access to resources Recommend Favorite